Minor histocompatibility antigen
Minor histocompatibility antigen (also known as MiHA) are peptides presented on the cellular surface of donated organs that are known to give an immunological response in some organ transplants.[1] They cause problems of rejection less frequently than those of the major histocompatibility complex (MHC). Minor histocompatibility antigens (MiHAs) are diverse, short segments of proteins and are referred to as peptides. These peptides are normally around 9-12 amino acids in length and are bound to both the major histocompatibility complex (MHC) class I and class II proteins.[2] Peptide sequences can differ among individuals and these differences arise from SNPs in the coding region of genes, gene deletions, frameshift mutations, or insertions.[3] About a third of the characterized MiHAs come from the Y chromosome.[4] Prior to becoming a short peptide sequence, the proteins expressed by these polymorphic or diverse genes need to be digested in the proteasome into shorter peptides. These endogenous or self peptides are then transported into the endoplasmic reticulum with a peptide transporter pump called TAP where they encounter and bind to the MHC class I molecule. This contrasts with MHC class II molecules's antigens which are peptides derived from phagocytosis/endocytosis and molecular degradation of non-self entities' proteins, usually by antigen-presenting cells. MiHA antigens are either ubiquitously expressed in most tissue like skin and intestines or restrictively expressed in the immune cells.[5]
Minor histocompatibility antigens are due to normal proteins that are in themselves polymorphic in a given population. Even when a transplant donor and recipient are identical with respect to their major histocompatibility complex genes, the amino acid differences in minor proteins can cause the grafted tissue to be slowly rejected. Several of the identified Autosomally and Y chromosome encoded MiHAs[4]
Known minor histocompatibility antigens
[edit]The following table lists the known MiHAs, the variant of genes encode MiHA peptides and their restricted HLA alleles.
| MiHA ID | MiHA peptide | Restricted HLA | Chromosome | Coordinate | SNP ID | Gene | Ensembl Gene ID |
|---|---|---|---|---|---|---|---|
| HA-1/A2 | VL[H/R]DDLLEA | A*02:01 | chr19 | 1068739 | rs1801284 | HMHA1 | ENSG00000180448 |
| HA-2 | YIGEVLVS[V/M] | A*02:01 | chr7 | 44977022 | rs61739531 | MYO1G | ENSG00000136286 |
| HA-8 | [R/P]TLDKVLEV | A*02:01 | chr9 | 2828765 | rs2173904 | KIAA0020 | ENSG00000080608 |
| HA-3 | V[T/M]EPGTAQY | A*01:01 | chr15 | 85579423 | rs2061821 | AKAP13 | ENSG00000170776 |
| C19ORF48 | CIPPD[S/T]LLFPA | A*02:01 | chr19 | 50798945 | rs3745526 | C19ORF48 | ENSG00000167747 |
| LB-ADIR-1F | SVAPALAL[F/S]PA | A*02:01 | chr1 | 179082165 | rs2296377 | TOR3A | ENSG00000186283 |
| LB-HIVEP1-1S | SLPKH[S/N]VTI | A*02:01 | chr6 | 12123016 | rs2228220 | HIVEP1 | ENSG00000095951 |
| LB-NISCH-1A | ALAPAP[A/V]EV | A*02:01 | chr3 | 52489389 | rs887515 | NISCH | ENSG00000010322 |
| LB-SSR1-1S | [S/L]LAVAQDLT | A*02:01 | chr6 | 7310026 | rs10004 | SSR1 | ENSG00000124783 |
| LB-WNK1-1I | RTLSPE[I/M]ITV | A*02:01 | chr12 | 889199 | rs12828016 | WNK1 | ENSG00000060237 |
| T4A | GLYTYWSAG[A/E] | A*02:01 | chr3 | 140688418 | rs9876490 | TRIM42 | ENSG00000155890 |
| UTA2-1 | QL[L/P]NSVLTL | A*02:01 | chr12 | 31981704 | rs2166807 | KIAA1551 | ENSG00000174718 |
| PANE1 | RVWDLPGVLK | A*03:01 | chr22 | 41940168 | rs5758511 | CENPM | ENSG00000100162 |
| SP110 | SLP[R/G]GTSTPK | A*03:01 | chr2 | 230207994 | rs1365776 | SP110 | ENSG00000135899 |
| ACC-1C | DYLQ[Y/C]VLQI | A*24:02 | chr15 | 79971064 | rs1138357 | BCL2A1 | ENSG00000140379 |
| ACC-1Y | DYLQ[Y/C]VLQI | A*24:02 | chr15 | 79971064 | rs1138357 | BCL2A1 | ENSG00000140379 |
| P2RX7 | WFHHC[H/R]PKY | A*29:02 | chr12 | 121167552 | rs7958311 | P2RX7 | ENSG00000089041 |
| ACC-4 | ATLPLLCA[R/G] | A*31:01 | chr15 | 78944951 | rs2289702 | CTSH | ENSG00000103811 |
| ACC-5 | WATLPLLCA[R/G] | A*33:03 | chr15 | 78944951 | rs2289702 | CTSH | ENSG00000103811 |
| LB-APOBEC3B-1K | [K/E]PQYHAEMCF | B*07:02 | chr22 | 38985821 | rs2076109 | APOBEC3B | ENSG00000179750 |
| LB-ARHGDIB-1R | LPRACW[R/P]EA | B*07:02 | chr12 | 14942624 | rs4703 | ARHGDIB | ENSG00000111348 |
| LB-BCAT2-1R | QP[R/T]RALLFVIL | B*07:02 | chr19 | 48799813 | rs11548193 | BCAT2 | ENSG00000105552 |
| LB-EBI3-1I | RPRARYY[I/V]QV | B*07:02 | chr19 | 4236999 | rs4740 | EBI3 | ENSG00000105246 |
| LB-ECGF-1H | RP[H/R]AIRRPLAL | B*07:02 | chr22 | 50525826 | rs112723255 | TYMP | ENSG00000025708 |
| LB-ERAP1-1R | HPRQEQIALLA | B*07:02 | chr5 | 96803547 | rs26653 | ERAP1 | ENSG00000164307 |
| LB-FUCA2-1V | RLRQ[V/M]GSWL | B*07:02 | chr6 | 143502020 | rs3762002 | FUCA2 | ENSG00000001036 |
| LB-GEMIN4-1V | FPALRFVE[V/E] | B*07:02 | chr17 | 746265 | rs4968104 | GEMIN4 | ENSG00000179409 |
| LB-PDCD11-1F | GPDSSKT[F/L]LCL | B*07:02 | chr10 | 103434329 | rs2986014 | PDCD11 | ENSG00000148843 |
| LB-TEP1-1S | APDGAKVA[S/P]L | B*07:02 | chr14 | 20383870 | rs1760904 | TEP1 | ENSG00000129566 |
| LRH-1 | TPNQRQNVC | B*07:02 | chr17 | 3690983 | rs3215407 | P2X5 | ENSG00000083454 |
| ZAPHIR | IPRDSWWVEL | B*07:02 | chr19 | 57492212 | rs2074071 | ZNF419 | ENSG00000105136 |
| HEATR1 | ISKERA[E/G]AL | B*08:01 | chr1 | 236554626 | rs2275687 | HEATR1 | ENSG00000119285 |
| HA-1/B60 | KECVL[H/R]DDL | B*40:01 | chr19 | 1068739 | rs1801284 | HMHA1 | ENSG00000180448 |
| LB-SON-1R | SETKQ[R/C]TVL | B*40:01 | chr21 | 33553954 | rs13047599 | SON | ENSG00000159140 |
| LB-SWAP70-1Q | MEQLE[Q/E]LEL | B*40:01 | chr11 | 9748015 | rs415895 | SWAP70 | ENSG00000133789 |
| LB-TRIP10-1EPC | G[E/G][P/S]QDL[C/G]TL | B*40:01 | chr19 | 6751268 | rs1049229 | TRIP10 | ENSG00000125733 |
| SLC1A5 | AE[A/P]TANGGLAL | B*40:02 | chr19 | 46787917 | rs3027956 | SLC1A5 | ENSG00000105281 |
| ACC-2 | KEFED[D/G]IINW | B*44:03 | chr15 | 79970875 | rs3826007 | BCL2A1 | ENSG00000140379 |
| ACC-6 | MEIFIEVFSHF | B*44:03 | chr18 | 63953532 | rs9945924 | HMSD | ENSG00000221887 |
| HB-1H | EEKRGSL[H/Y]VW | B*44:03 | chr5 | 143820488 | rs161557 | HMHB1 | ENSG00000158497 |
| HB-1Y | EEKRGSL[H/Y]VW | B*44:03 | chr5 | 143820488 | rs161557 | HMHB1 | ENSG00000158497 |
| DPH1 | S[V/L]LPEVDVW | B*57:01 | chr17 | 2040586 | rs35394823 | DPH1 | ENSG00000108963 |
| UTDP4-1 | R[I/N]LAHFFCGW | DPB1*04 | chr9 | 128721272 | rs11539209 | ZDHHC12 | ENSG00000160446 |
| CD19 | WEGEPPC[L/V]P | DQB1*02:01 | chr16 | 28933075 | rs2904880 | CD19 | ENSG00000177455 |
| LB-PI4K2B-1S | SRSS[S/P]AELDRSR | DQB1*06:03 | chr4 | 25234395 | rs313549 | PI4K2B | ENSG00000038210 |
| LB-MTHFD1-1Q | SSIIAD[Q/R]IALKL | DRB1*03:01 | chr14 | 64442127 | rs2236225 | MTHFD1 | ENSG00000100714 |
| LB-LY75-1K | LGITYR[N/K]KSLMWF | DRB1*13:01 | chr2 | 159819916 | rs12692566 | LY75 | ENSG00000054219 |
| SLC19A1 | [R/H]LVCYLCFY | DRB1*15:01 | chr21 | 45537880 | rs1051266 | SLC19A1 | ENSG00000173638 |
| LB-PTK2B-1T | VYMND[T/K]SPLTPEK | DRB3*01:01 | chr8 | 27451068 | rs751019 | PTK2B | ENSG00000120899 |
| LB-MR1-1R | YFRLGVSDPI[R/H]G | DRB3*02:02 | chr1 | 181049100 | rs2236410 | MR1 | ENSG00000153029 |
T cell Response to MiHAs
[edit]The MiHAs bound to a MHC presented on a cell surface may be recognized as a self peptide or not recognized by either CD8+ or CD4+ T cells. The lack of recognition of a T cell to this self antigen is the reason why allogeneic stem cell transplantation for an HLA matched gene or a developing fetus’s MiHAs during pregnancy may not be recognized by T cells and marked as foreign leading to an immune response. Although B cell receptors can also recognize MHCs, immune responses seem to only be elicited by T cells.[6] The consequences of an immune response are seen in allogeneic hematopoietic stem cell transplantation (HCT) when the peptides encoded by polymorphic genes differ between the recipient and the donor T cells. As a result, the donor T cells can target the recipients cells called graft-versus-host disease (GVHD).[5] Although graft or bone marrow rejection can have detrimental effects, there are immunotherapy benefits when cytotoxic T lymphocytes are specific for a self antigen and can target antigens expressed selectively on leukemic cells in order to destroy these tumor cells referred to as graft-versus- leukemia effect (GVL).[3]
The recognition of a mature T cell to this self antigen should not induce an immune response. During thymic selection occurring in the thymus, only a thymocyte TCR that recognizes either class I or class II MHC molecule plus peptide should survive positive selection. However, there is death by apoptosis of thymocytes that do not interact with MHC molecules or have high-affinity receptors for self MHC plus self antigen a process referred to as negative selection. Therefore, the process of positive and negative selection means fewer self-reactive mature T cells will leave the thymus and lead to autoimmune problems.
Discovery of MiHAs
[edit]The significance of MiHAs in an immune response was recognized following transplantation. The recipient developed GVHD despite having a HLA- matched genes at the Major Histocompatibility locus. The experiment raised questions about the possibility of there being MiHAs. More specifically, the first MiHA was discovered when bone marrow transplantation occurred between opposite sexes. The female recipient obtained MHC-matched bone marrow cells but still had active cytotoxic T cells (CD8+).[3] The CD8+ T cells were active and targeted the male bone marrow cells. The male bone marrow cells were found to be presenting a peptide in the MHC groove encoded by a gene on Y chromosome. The peptide was foreign to the female T cells and females lack the Y chromosome and, thus, this MiHA. The MiHAs encoded by the Y chromosome are known as HY antigens.[3]
H-Y Antigen
[edit]H-Y antigens are encoded by genes on the Y chromosome. Both HLA class I and II alleles have been found to present these antigens. Some of these antigens are ubiquitously expressed in nucleated male cells, and the presence of these antigens has been associated with a greater risk of developing GVHD allogeneic stem cell transplantation for a HLA matched gene when there's a male recipient and female donor.[7] H-Y MiHA play a role in pregnancy with a male fetus because fetal cells can cross from the placenta into the maternal blood stream where the maternal T cells respond to the foreign antigen presented on both MHC class I and II. Therefore, H-Y specific CD8+ T cells develop in the maternal blood and can target the fetal cells with nucleus expressing the antigen on a MHC class I molecule. The response to these fetal H-Y antigens are involved with women experiencing secondary recurrent miscarriage who were previously pregnant with a male fetus.[3] Women with an earlier male pregnancy have T cells which were previously exposed to these H-Y antigens, and consequently recognize them quicker. It has been found that women with recurrent miscarriage also contain MHC II with ability to present these antigens to T helper cells (CD4+) which is significant for CD8+ activation.[8]
Histocompatibility Antigen 1 (HA1)
[edit]HA1 results from a SNP converting the nonimmunogenic allele (KECVLRDDLLEA) to an immunogenic allele (KECVLHDDLLEA). This SNP results in better peptide binding ability to the groove of a particular MHC class I molecules found on antigen presenting cells.[5] The significance of the peptide changing to an immunogenic form is that now specific HLA-A 0201 restricted T cells can recognize the peptide presented by MHC class I HLA-A0201 molecules. This recognition leads to an immune response if the T cells recognize the peptide as foreign. This recognition occurs when an individual lacks the immunogenic version of the peptide, but is exposed to the HA-1 peptide during pregnancy or allogeneic stem cell transplantation. During pregnancy, the fetal HA-1 has been found to originate in the placenta and specific maternal CD8+ T cells recognizing this MiHA have been identified.[5]
Immunotherapy Graft-Versus- Leukemia Effect
[edit]CD8+ T cells that are specific for a MiHA can target these antigens when they are expressed specifically on tumor cells, which allows for the destruction of harmful tumor cells. In mice, allogeneic stem cell transplantation donor CD8+ T cells specific for a MiHA found in the recipient has been shown to inhibit the division of leukemic cells. However, there is a risk in developing GVHD if the T cells are specific for MiHAs expressed ubiquitously on epithelial cells. More specifically, HA-8, UGT2B17 and SMCY MiHAs that are ubiquitously expressed present a higher risk of developing GVHD. Therefore, in order to prevent adverse GVHD effects, immune cell restricted MiHAs are ideal targets for graft-versus- leukemia (GVL) since not all nucleated cells are targeted by responding T cells. An example of an ideal target is the MiHA HB-1, which is highly expressed in harmful B cells, but has a low expression in other tissue cells.[9]
Clinical implications
[edit]Immunisation of mothers against male-specific minor histocompatibility (H-Y) antigens has a pathogenic role in many cases of secondary recurrent miscarriage, that is, recurrent miscarriage in pregnancies succeeding a previous live birth. An example of this effect is that the male:female ratio of children born prior and subsequent to secondary recurrent miscarriage is 1.49 and 0.76 respectively.[10]
See also
[edit]References
[edit]- ^ Robertson NJ, Chai JG, Millrain M, Scott D, Hashim F, Manktelow E, Lemonnier F, Simpson E, Dyson J (March 2007). "Natural regulation of immunity to minor histocompatibility antigens". Journal of Immunology. 178 (6): 3558–65. doi:10.4049/jimmunol.178.6.3558. PMID 17339452.
- ^ Dzierzak-Mietla M, Markiewicz M, Siekiera U, Mizia S, Koclega A, Zielinska P, Sobczyk-Kruszelnicka M, Kyrcz-Krzemien S (2012). "Occurrence and Impact of Minor Histocompatibility Antigens' Disparities on Outcomes of Hematopoietic Stem Cell Transplantation from HLA-Matched Sibling Donors". Bone Marrow Research. 2012: 257086. doi:10.1155/2012/257086. PMC 3502767. PMID 23193478.
- ^ a b c d e Linscheid C, Petroff MG (April 2013). "Minor histocompatibility antigens and the maternal immune response to the fetus during pregnancy". American Journal of Reproductive Immunology. 69 (4): 304–14. doi:10.1111/aji.12075. PMC 4048750. PMID 23398025.
- ^ a b Hirayama M, Azuma E, Komada Y (2012). Major and Minor Histocompatibility Antigens to Non-Inherited Maternal Antigens (NIMA), Histocompatibility. INTECH. p. 146. ISBN 978-953-51-0589-3.
- ^ a b c d Bleakley M, Riddell SR (March 2011). "Exploiting T cells specific for human minor histocompatibility antigens for therapy of leukemia". Immunology and Cell Biology. 89 (3): 396–407. doi:10.1038/icb.2010.124. PMC 3061548. PMID 21301477.
- ^ Perreault C, Décary F, Brochu S, Gyger M, Bélanger R, Roy D (1990). "Minor histocompatibility antigens" (PDF). Blood. 76 (7): 1269–80. doi:10.1182/blood.V76.7.1269.1269. PMID 2207305.
- ^ Nielsen HS (2011-07-01). "Secondary recurrent miscarriage and H-Y immunity". Human Reproduction Update. 17 (4): 558–74. doi:10.1093/humupd/dmr005. PMID 21482560.
- ^ Lissauer D, Piper K, Goodyear O, Kilby MD, Moss PA (July 2012). "Fetal-specific CD8+ cytotoxic T cell responses develop during normal human pregnancy and exhibit broad functional capacity". Journal of Immunology. 189 (2): 1072–80. doi:10.4049/jimmunol.1200544. PMID 22685312.
- ^ Bleakley M, Riddell SR (2004). "Molecules and mechanisms of the graft-versus-leukaemia effect". Nature Reviews. Cancer. 4 (5): 371–80. doi:10.1038/nrc1365. PMID 15122208. S2CID 35740723.
- ^ Nielsen HS (2011). "Secondary recurrent miscarriage and H-Y immunity". Human Reproduction Update. 17 (4): 558–74. doi:10.1093/humupd/dmr005. PMID 21482560.
External links
[edit]- Minor+histocompatibility+antigens at the U.S. National Library of Medicine Medical Subject Headings (MeSH)